Background and Objective For people with cystic fibrosis, validated patient-reported outcome measures for the assessment of the complex abdominal involvement are lacking. The objective of this study was to examine whether the CFAbd-Score, a novel questionnaire consisting of 28 items, meets the essential requirements (validity and reliability) for a patient-reported outcome measure according to US Food and Drug Administration recommendations. Methods Content validity was assessed by recording the frequencies and severity of symptoms that occurred during the prior 2 weeks in patients with cystic fibrosis (n = 116; aged ≥ 6 years). Comparing the CFAbd-Score results obtained from patients with cystic fibrosis and healthy controls (n = 88), we determined known-groups validity. To explore the structure of the patient-reported outcome measure, a factor analysis was conducted. Internal consistency of the five extracted score domains was assessed using Cronbach's alpha. For test-retest reliability, a subgroup of patients (n = 43) was reevaluated and intra-class correlation coefficients were determined. Results The CFAbd-Score differentiated patients with cystic fibrosis from healthy controls with a large effect size (17.3 ± 1.1 vs. 8.0 ± 0.7 points; p < 0.001; Cohen's d = 0.85). Items, domains, and scores reflected the relevance to patients with cystic fibrosis and allowed a differentiation between subgroups of patients with cystic fibrosis (e.g., patients with and without abdominal pain, pancreatic sufficiency, and age groups). High item-domain loadings as well as good to excellent internal consistency and reproducibility (Cronbach's α = 0.70-0.92; intra-class correlation coefficient = 0.932, 95% confidence interval 0.874-0.963) indicated construct validity and reliability. Conclusions The CFAbd-Score has successfully passed through key steps of the iterative process of patient-reported outcome measure development. Prospectively, the CFAbd-Score is proposed as a patient-centered instrument for monitoring abdominal symptoms and, most interestingly, for evaluating changes in symptoms with novel treatments such as cystic fibrosis transmembrane regulator modulators. Trail Registration ClinicalTrials.gov: NCT03052283.
Introduction
Cystic fibrosis (CF) is the most common, inherited autosomal recessive disease in populations of Caucasian descent. In Europe, albeit with regional differences, one in approximately 3300 newborns is affected. The disease-causative mutations of the cystic fibrosis transmembrane regulator (CFTR)-encoding gene result in the total or partial absence or loss of function of the CFTR protein, the main transmembrane transporter for chloride and bicarbonate in the apical membrane of secretory and absorptive epithelial cells. The CFTR regulates the respiratory and gastrointestinal (GI) surface liquid layer and, thereby, mucous viscosity and mucociliary clearance. It also drives the alkalization required for digestion and absorption in the duodenum.
The survival of people with CF has extended significantly and the disease increasingly transits into adulthood [1] . Thus, beyond the pulmonary manifestation in CF, increased attention needs to be paid to the CF-associated comorbidities of the GI tract. These are already pronounced in childhood, but may progress and culminate in chronic manifestations [2] [3] [4] [5] [6] . "How can we relieve gastro-intestinal symptoms, such as stomach pain, bloating and nausea in people with CF" is the second ranked question in a recent survey conducted to identify the most important research priorities to the CF community [7] . This large survey, which includes the responses of more than 500 patients with CF and healthcare providers, clearly underlines the need to highlight GI complications more strongly to clinicians and scientists. The growing demand for GI experts in CF has been recognized and is recently being addressed, for instance, by large funding initiatives offered by the Cystic Fibrosis Foundation such as the DIGEST Program [8] . Numerous recent publications demonstrate the strong incentive to increase knowledge on the abdominal involvement in CF, and to improve its management [9] [10] [11] [12] [13] [14] . A broader understanding of the complex multi-organ abdominal involvement in CF may improve early treatment options and more specifically the GI manifestations. Moreover, with the introduction of new potent CFTR modulators and their more widespread use [15] , it is of high interest to assess changes in abdominal symptoms with this therapy. In this regard, but also to support routine disease management decisions, validated CF-specific and patient-centered instruments for measuring these symptoms will be most helpful.
With this in mind, we developed a questionnaire intended as a patient-reported outcome measure (PROM) aiming to assess the abdominal involvement in CF in a structured and systematic manner. In two previous studies using preliminary versions of the questionnaire, we examined relationships between the deduced score and the genotype, clinical history, laboratory parameters [16] , and abdominal ultrasound findings [17] . In a first study using the first version of the questionnaire (formerly named JenAbdomen-CF Score), we showed that scores were significantly higher in patients with more severe genotypes, exocrine pancreatic insufficiency (EPI), and with history of abdominal complications as well as surgery [16] . The main finding of the second study was that pancreatic lipomatosis in particular is associated with an increased abdominal symptom load [17] .
The present study is the next step in the validation process of our further developed score as a CF-specific psychometric instrument (now named CFAbd-Score). The primary objective was to confirm the conceptual framework and to assess the validity and reliability of the questionnaire. With detail, we assessed whether items, domains, and general scores reflect what is important to patients (content validity) and whether differences exist between patients with CF and healthy controls (known-groups validity). Factorial validity was assessed to explore the logical structure of the PROM. Reliability was proven by testing for internal consistency and stability of the score over time.
Materials and Methods

Patients
Of the 145 patients with CF who regularly attended the CF-Center of the University Hospital in Jena (Germany) in 2017, 129 participated in the study. Thirteen of them were excluded from this evaluation because they were aged under 6 years (n = 116). Diagnosis of CF was based on two positive sweat tests (Cl − ≥ 60 mmol/L) and/or the detection of two CFTR mutations with evidence of organ involvement. The patients completed the one-sided paper questionnaire during their routine outpatient appointment with the ability to clear up queries. A subgroup of patients (n = 43) was reevaluated at their next appointment, which usually occurred in quarterly intervals. Each questionnaire took ~ 5-10 min to complete.
Healthy Controls
Healthy volunteers were recruited by posting notices on the bulletin board of the Jena University Hospital. In total, 102 persons enrolled for the study. Fourteen subjects were excluded from analysis because of reported abdominal problems owing to food intolerances, allergies, and/or celiac diseases.
Key Points for Decision Makers
The gastrointestinal involvement in cystic fibrosis (CF) is, besides the pulmonary manifestation, one of the most important research priorities to the CF community.
The novel CFAbd-Score is a patient-reported outcome measure for the identification and quantification of abdominal symptoms and their influence on quality of life in CF.
Here, we demonstrate that the CFAbd-Score measures the concept of interest (content validity), differentiates between distinct groups (known-groups validity), and is able to yield consistent and reproducible estimates (reliability). Thus, the CFAbd-Score fulfills key requirements for a patient-reported outcome measure.
Questionnaire
The CFAbd-Score is the third version of a patient-centered questionnaire [16, 17] . In 2009, the US Food and Drug Administration published a guideline for the development of PROMs as reliable instruments [18] . During the iterative process of development, we followed these recommendations as illustrated in the score's development history shown in Fig. S1 of the Electronic Supplementary Material (ESM). The present version consists of 28 items that are grouped into five generic domains: pain symptoms (four items), disorders of bowel movement (eight items), disorders of eating and appetite (five items), gastroesophageal reflux (GER) symptoms (three items), and impairment of quality of life (QoL, eight items). Items refer to a recall period of the preceding 2 weeks. The respondents were requested to answer on a six-point Likert scale either on a true-false rating ranging from "no problem" to "problem is as bad as it can be", or on a frequency response ranging from "not at all/never" to "always/daily". Pain intensity was rated on a scale from 0 ("no pain") to 10 ("worst pain imaginable") with mood-expressing faces, and pain duration was rated on a time scale.
After cognitive interviewing of patients and parents, we decided to apply the PROM in children aged < 12 years in a proxy-assisted form. We chose a simple variant of a query structure that combined both self-and proxy-assisted ratings (e.g., "Please rate to what extent you have/your child has experienced the following symptoms …"). Primarily, such a structure was chosen to ensure that the content validity and other measurement properties of self-reports and proxyassisted reports are similar to each other [18] .
Based on the previous version of our questionnaire [17] , two additional questions on bowel movement/stool characteristics were added ("foul-smelling stool", "stool frequency") as qualitative work and clinical experience indicated their importance. A total of 28 items were evaluated. The domain points were calculated as the sum of the items answered over the maximum item points per domain. On the basis of binary logistic regression coefficients, the domains were weighted and the CFAbd-Score was calculated on a scale between 0 and 100 with higher values for increasing frequency and/or severity of symptoms.
Data Management and Analyses
The data were checked for completeness and entered into a database. On the patient data set, an exploratory factor analysis with oblique rotation was conducted. By inspection of scree plots and eigenvalues, the number of factors to be retained as indicators of domains was identified. Internal consistency of the extracted domains was evaluated using Cronbach's alpha [19] . Estimates of α > 0.60 were expected [19, 20] . Differences between patients and healthy subjects and between subgroups of patients were tested using either the T test or Mann-Whitney U test, following Kolmogorov-Smirnov testing of normal distribution. Effect size for anticipated group differences was estimated with Cohen's d and was considered small (0.20), medium (0.50), or large (0.80) in magnitude [21] . Differences in symptom frequency between subgroups of patients with CF were detected with the Chi-squared test. Based on the CFAbd-Score results of patients and the healthy cohort, a receiver operating characteristic curve was plotted. The optimal cut-off score was identified on the basis of the maximum specificity, which was not higher than sensitivity and was defined as the value at which the Youdenʼs index (sensitivity + specificity − 1) was highest [22] . The intra-class correlation coefficient (ICC) of the CFAbd-Score and its domains was determined using a two-way mixed-effects model with "absolute agreement" definition [23] . Based on the 95% confidence interval of the ICC estimate, values < 0.5, between 0.5 and 0.75, between 0.75 and 0.9, and > 0.90 indicated poor, moderate, good, and excellent reliability, respectively [23] . An ICC > 0.7 was expected [24] . Additionally, a Bland-Altman plot was constructed to graphically illustrate and describe the agreement between the test and retest. Statistical analyses were performed with SPSS software, Version 24 (SPSS Inc., Chicago, IL, USA). Differences were considered significant at p ≤ 0.05.
Results
Participants
The characteristics of the patients with CF are given in Table 1 . The mean age of the patient cohort was 23.3 years. The healthy cohort consisted of 55 female individuals (62.5%) and 33 male individuals. The mean age of the healthy group was 25.5 years. In this group, adults accounted for 64.8% (n = 57) and participants aged younger than 12 years accounted for 23.9% (n = 21).
Validity
CFAbd-Score Differences between Patients and Healthy Subjects (Known-Groups Validity)
In patients with CF, the mean CFAbd-Score was significantly higher compared with the healthy controls (17.3 ± 1.1 vs. 8.0 ± 0.7 points; p < 0.001; Fig. 1a ). The effect size for anticipated group differences estimated with Cohen's d [21] was large in magnitude (0.85). There were no differences between juvenile (age 6-17 years; 17.0 ± 1.7 points) and adult patients with CF (17.5 ± 1.4 points; not shown).
Further subdividing children and adolescents with CF aged 6-11 years and 12-17 years showed no intra-group differences between the age groups (17.4 ± 2.4 vs. 16.4 ± 2.5, respectively; not shown). Moreover, no sex-related differences were observed in any age group (not shown). To determine the discriminatory ability of the score, a receiver operating characteristic curve was plotted. The area under the receiver operating characteristic curve indicated good performance of the questionnaire (0.77, 95% confidence interval 0.70-0.83, p < 0.001; Fig. 1b) . The cut-off score with the most acceptable specificity to sensitivity was 9.6 (Youden's index = 0.43 [22] ), with 70% of the healthy group being below this value (negative predictive value = 0.70) and 73% of the patients with CF being above this value (positive predictive value = 0.73; Fig. 1c ).
Frequencies of Abdominal Symptoms (Content Validity)
Of our patients with CF, 98% had at least one abdominal symptom; only two out of 116 patients were symptom free during the recall period. The most common symptoms were foul-smelling stools and flatulence, which were reported by 78% and 77% of the patients with CF, respectively (Fig. 2) . Abdominal pain was experienced by 72%, and nearly onethird (31%) of the patients stated that they had pain at least two to three times during the previous 2 weeks. Another prominent symptom was a lack of appetite, which affected every second patient. In general, all of the 28 items requested were important to the patients and reflected patient concerns as none of the items were never reported, supporting that the instrument measures what it is intended to measure.
CFAbd-Score Differences between Subgroups of Patients with Cystic Fibrosis
Among our patients, one of the leading symptoms was abdominal pain. This item was recorded in the dimensions of frequency, intensity, and duration. Thirty of 116 patients reported on at least two to three episodes of abdominal pain with an intensity of '4' or higher and/or a duration of 45 min minimum, thus, constituting a relevant burden. For these patients, the calculated CFAbd-Score was significantly higher compared with the patients who were free of abdominal pain during the recall period (30.3 ± 2.1 vs. 9.9 ± 1.1; p < 0.001; not shown). Remarkably, these patients also reported more frequently on other symptoms than pain and scored significantly higher in all score domains (Fig. 3) . Of the 30 patients who had experienced pain to the described extent, 63% were children and adolescents. In general, pain was more common among children and adolescents, whereas adult patients reported more often on heartburn and impairment of QoL aspects, such as fatigue (Fig. 4) .
In general, our patients with EPI reported more frequently on disorders of bowel movement and related discomfort than patients with pancreatic sufficient (PS) CF (Table 2) . However, of the nine PS patients, three stated that they had fatty stools once during the recall period. Interestingly, these patients also scored higher in the pain domain than the other PS patients (35.0 ± 7.6 vs. 13.3 ± 4.4 domain points; not shown). Another interesting finding was that patients with a milder class IV-VI mutation on the second allele (n = 16) reported more often on abdominal pain than patients with two severe mutations. Six of these patients were PS and ten had previously been diagnosed with pancreatic lipomatosis [17] . Patients with a history of distal intestinal obstruction Patients who presented with pain had at least two to three episodes of pain during the previous 2 weeks, rated with at least '4' on a scale from 0 to 10 and/or 45 min minimum duration. GER gastroesophageal reflux, QoL quality of life syndrome were more frequently affected by a lack of appetite and the need to force themselves to eat than patients without distal intestinal obstruction syndrome.
Reliability
Quality of Data, Factorial Validity, and Internal Consistency
In total, 247 questionnaires were analyzed. The percentage of missing data was low (1.7%). A plausibility check revealed a total of 0.8% of the answers to be dubious (e.g., 'abdominal pain frequency' = 0 together with 'abdominal pain duration' = 2). To deal with missing and excluded data, the respondent central tendency option [20] was chosen and the formula for calculation of the domain points was adapted accordingly. The low Bartlett's test significance level (p < 0.001) and a Kaiser-Meyer-Olkin coefficient of 0.81 indicated the suitability of data for structure detection by a factor analysis. Five factors/domains were extracted based on the Kaiser criterion (eigenvalues ≥ 1; Table 3 ). By these five domains, 60% of the total variance was explained. Two more factors had eigenvalues ≥ 1 but there was substantial cross-loading of items and, therefore, a five-domain solution was considered most meaningful. The majority of items loaded onto the resulting domain with r > 0.40 (89.3%) and correlated more highly with their intended domain than a competing domain (92.9%), supporting the conceptual model (Table S1 of the ESM). Internal consistency coefficients (Cronbach's alpha) indicated good to excellent reliability of the domains (Table 3) . Fig. 4 Differences in experienced symptoms between juvenile and adult patients with cystic fibrosis. Percentage of patients who reported to have had the respective symptom at least two to three times during the previous 2 weeks Table 2 Differences in abdominal symptoms between subgroups of patients with cystic fibrosis. Occurrence of symptoms during the previous 2 weeks DIOS distal intestinal obstruction syndrome, EPI exocrine pancreatic insufficiency, PS pancreatic sufficiency a Grades 3-6 on a 6-point Likert scale corresponding to 'occasionally' or more frequently (at least two to three times during the last 2 weeks), and 'mild or slight problem' or more severe b Abdominal pain' included 'frequency', together with 'intensity' or 'duration' (all at least grade 3 on a 6-point Likert scale). Answers rated as grade 2 account for the difference between "yes" + "no" and 100% for each item 
Test-Retest Reliability
The degree of correlation between the first (test) and the second responses (retest) of the CFAbd-Score questionnaire was determined by ICC analysis. From the 95% confidence interval of the CFAbd-Score ICC, we concluded that the reliability of our score was good to excellent, as the true ICC value was supposed to be still greater than 0.874 (Fig. 5a ). An ICC estimate for the score of 0.932 indicated that 93% of the variability in the score captured by that measure represented the construct and only 7% represented random variation. Intra-class correlation coefficients of the score domains were consistently > 0.8 (not shown). A Bland-Altman plot was used to illustrate the agreement between the test and retest. All estimates but one were within the 95% limits of agreement (average difference ± 1.96 standard deviation of the difference). Mean disagreement was 0.6 score points between the test and retest (Fig. 5b) . The box plot graphics indicate a similar degree of data distribution between the test and retest (Fig. 5c ). There was no difference between mean test and retest CFAbd-Score points (18.0 vs. 17.5; p = 0.560).
Of the 43 patients included in this test-retest analysis, ten patients were aged 6-11 years.
Discussion
Currently, several disease-specific psychometric instruments are available for patients with CF: the Cystic Fibrosis Quality of Life (CFQoL) questionnaire [26] , the Questions on Life Satisfaction for Adolescents and Adults with Cystic Fibrosis (FLZ M -CF) [27] , the Cystic Fibrosis Questionnaire (CFQ) [28] , and its further development the CFQ-Revised (CFQ-R) [29] , which at present is most frequently applied.
All of these questionnaires, however, mainly itemize psychosocial health and gather comparatively few aspects of the abdominal symptomatology in CF. The Pediatric Quality of Life Inventory (PedsQL™) module on GI symptoms is a comprehensive metric for the assessment of symptoms related to functional and organic GI disorders in pediatric patients [30] . However, this PROM is not CF specific and important issues that affect people with the inherited disease are insufficiently assessed. Recently, a 27-item questionnaire developed as a PROM for patients with chronic pancreatitis including CF-related EPI has been published [31] . This questionnaire covers both GI symptoms and health-related QoL. The first application in a small CF collective indicated content validity of the conceptual model, but altogether, a psychometric evaluation of this questionnaire based on a larger CF patient cohort has yet to be done.
In the present study, we tested the third improved version of our questionnaire and assessed the main quality criteria validity and reliability. As a first result, we show that the CFAbd-Score differentiates between patients with CF and healthy subjects with a large effect size, supporting content validity. This finding is particularly important with regard to the further scientific and clinical use of the CFAbd-Score: only knowing the score ranges of patients with CF compared to healthy controls allows estimations of relevant longitudinal changes, e.g., following therapeutic interventions. This is of particular interest for appraising the effectiveness of novel therapies targeting the abdominal involvement in CF. Concurrently, we show that considerable differences in the symptom burden may exist among patients with CF, and for a small portion of patients, the score will overlap with otherwise healthy subjects (Fig. 1) . Thereby, abdominal symptoms also may affect healthy subjects, and we would expect that a healthy person may tend to assess unusual abdominal The higher the agreement, the closer the mark is to the zero line on the y-axis. c Variation between the test and retest is depicted by box plots. SD Standard deviation symptoms, should they arise, with greater emphasis than a patient with CF who may be accustomed to such symptoms.
Our findings underline that during the preceding 2 weeks, 72% of the included patients with CF experienced abdominal pain, and nearly one-third (31%) of the patients had pain at least two to three times (Fig. 2) . These data are consistent with our previous observations [16] and further support the content validity of our questionnaire. In patients with CF, pain is associated with anxiety, depression, restriction of work/school and daily activities, poor physical function, impairment of sleep, and overall lower QoL, and may thus impact adherence to treatment (rev. in [32, 33] ). We confirm that in patients with CF abdominal pain is related to additional restrictions in QoL (Fig. 3) , but also to further symptoms associated with bowel movement, GER, and eating. Particularly in children, a lack of appetite is a significant concern. Every third of our juvenile patients experienced this symptom at least two to three times during the recall period (Fig. 4) . Critically, olfactory and gustatory dysfunction, which are considerably more frequent in patients with CF than in age-matched healthy controls [34] , may decrease appetite and aggravate nutritional problems in patients with CF. However, the etiology of a CF-related reduced appetite is multifactorial and is far from being fully understood. The authors of a recent review emphasize that validated scoring systems for grading appetite are needed and that the best objective measure for evaluating appetite is yet to be defined [35] . Our data may give a first hint that a poor appetite is associated with abdominal pain in CF.
Heartburn, acid regurgitation, and non-acid reflux are frequent CF-related symptoms subsumed as GER. Over time, GER may cause troublesome complications such as esophagitis or Barrett's esophagus and is then referred to as GER disease [36] . Interestingly, among patients with CF, heartburn was a much greater problem in adults compared with children and adolescents (Fig. 4, [16] ). This accords well with increasing rates of pulmonary hyperinflation and cough with progressive pulmonary destruction, which is more frequent with higher ages. Gastroesophageal reflux renders patients with CF more prone to pulmonary aspiration of gastric contents [37] , and airway acidification is associated with respiratory exacerbations [38] . In a significant percentage of patients with CF, heartburn and acid regurgitation persist on acid suppression therapy [39] . Remarkably, even the use of proton pump inhibitors was associated with an increased frequency of pulmonary exacerbations [40] . In this regard, a recent review concluded that GER disease in CF is often over-treated and that more data regarding the safety and efficacy of acid suppression in CF are needed [36] . The management of GER disease is challenging and strategies should encompass diet and lifestyle changes as well as pharmacological and surgical approaches. An interesting finding is that patients with a milder class IV-VI CFTR mutation on the second allele were more often and more severely affected by abdominal pain than patients with two severe class I-III mutations. We attribute this finding to the significantly elevated risk of developing pancreatitis in primarily PS patients with a mild CFTR genotype, compared with patients with moderate-to-severe genotypes [25] . As revealed by serial sonography, the progression from PS to EPI proceeds via four states: normal pancreas, an atrophic state subsequent to recurrent pancreatitis, a lipomatous state in which pancreatic tissue is successively replaced by fat-dense tissue, and a macro-or microcystic pancreas with parietal calcifications [41] . In the long term, many patients who were initially classified as PS will become EPI [42] , experiencing intermittent or chronic pancreatitis, which frequently is symptomatic and accompanied by abdominal pain [12] . Accordingly, among our PS patients, a patient who has recurrent pancreatitis scored highest with 36.2 CFAbdScore points. In this regard, pancreatic lipomatosis, which was sonographically detected in 10 of 16 patients carrying a class IV-VI mutation, has also been related to a higher symptom burden [17] .
As a next essential step, we are constructing age-adapted versions of our questionnaire, specifically for preschoolers and primary-school aged children. It is important to consider fairly narrow age groupings to account for developmental differences and to determine the lower age limit at which children can understand the questions and provide reliable and valid responses that can be compared across age categories [18] . Particularly with regard to those items targeting mood, emotion, and other subjectively assessed aspects, ageadapted versions are reasonable to avoid proxy bias.
Overall, we show that the assessed items, domains, and scores reflect the importance of symptoms to our patients. Furthermore, we identified significant differences in CFAbdScores between patients with CF and healthy controls, as well as between subgroups of patients, supporting content and construct validity. Assessment of measurement properties revealed good performance of our questionnaire: strong loadings of items on their intended domain, and internal consistency of the score domains (Cronbach´s alpha > 0.60 [19, 20] ), and a strong intra-class correlation between the test and retest (ICC > 0.7 [24] ) indicated construct validity and reliability of the CFAbd-Score. Our next step is to determine the sensitivity of the instrument to capture and quantify changes, using the CFAbd-Score in interventional studies as well as steadily and longitudinally in clinical practice.
Conclusion
We demonstrate that the CFAbd-Score fulfills key requirements for PROMs defined by the US Food and Drug Administration such as content validity (the instrument measures the concept of interest), construct validity (the instrument can differentiate between distinct groups), and reliability (the instrument is able to yield consistent and reproducible estimates). Besides its use in clinical practice, it is of high interest to implement the CFAbd-Score in studies, e.g., examining the effects of novel therapies such as CFTR modulators, on the abdominal symptoms in patients with CF.
